Research programme: STAC-BBB based therapeutics - Astellas Gene Therapies/SangamoTherapeutics
Latest Information Update: 01 Apr 2025
At a glance
- Originator Sangamo Therapeutics
- Developer Astellas Gene Therapies; Sangamo Therapeutics
- Class Proteins; Transcription factors
- Mechanism of Action DNA-binding protein modulators; Genetic transcription modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Neurological disorders
Most Recent Events
- 31 Dec 2024 Preclinical trials in Neurological disorders in USA (Parenteral) prior to December 2024
- 19 Dec 2024 Astellas Gene Therapies and Sangamo Therapeutics enters into a licensing agreement for STAC-BBB to develop genomic medicines to treat certain neurodegenerative diseases
- 19 Dec 2024 Early research in Neurological disorders in USA (Parenteral)